Download PDF
Gastroenterologie up2date 2022; 18(02): 92-93
DOI: 10.1055/a-1790-1968
Studienreferate

Kommentar

› Further Information
Also available at
    Permissions and Reprints All articles of this category

Die Ergebnisse der Phase-II-Studie CheckMate 142 bestätigen die Rolle der Immuntherapie als bahnbrechende therapeutische Strategie für MSI/dMMR metastasierte Kolorektalkarzinome (mKRK).



Publication History

Article published online:
01 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Comment to this article:

Kombinierte Checkpointblockade in der Erstlinie bei MSI-H/dMMR mCRCGastroenterologie up2date 2022; 18(02): 92-92
DOI: 10.1055/a-1792-0780

 

  • Literatur

  • 1 André T, Shiu KK, Kim TW. et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 383: 2207-2218
    CrossrefPubMedGoogle Scholar
  • 2 Overman MJ, Lonardi S, Wong KYM. et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 2018; 36: 773-779
    CrossrefPubMedGoogle Scholar
  • 3 Venderbosch S, Nagtegaal ID, Maughan TS. et al. Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clin Cancer Res 2014; 20: 5322-5330
    CrossrefPubMedGoogle Scholar